| On the origins of drug polypharmacology X Jalencas, J Mestres MedChemComm 4 (1), 80-87, 2013 | 161 | 2013 |
| Identification of Pim kinases as novel targets for PJ34 with confounding effects in PARP biology AA Antolín, X Jalencas, J Yélamos, J Mestres ACS Chemical Biology 7 (12), 1962-1967, 2012 | 81 | 2012 |
| Identification of Similar Binding Sites to Detect Distant Polypharmacology X Jalencas, J Mestres Molecular Informatics 32 (11‐12), 976-990, 2013 | 53 | 2013 |
| Chemoisosterism in the Proteome X Jalencas, J Mestres Journal of chemical information and modeling 53 (2), 279–292, 2013 | 30 | 2013 |
| The human endogenous metabolome as a pharmacology baseline for drug discovery A Bofill, X Jalencas, TI Oprea, J Mestres Drug Discovery Today, 2019 | 10 | 2019 |
| Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington’s disease SM Galyan, CY Ewald, X Jalencas, S Masrani, S Meral, J Mestres Scientific Reports 12 (1), 1-14, 2022 | 6 | 2022 |
| Design, Quality and Validation of the EU-OPENSCREEN Fragment Library Poised to a High-Throughput Screening Collection X Jalencas, H Berg, LO Espeland, S Sreeramulu, F Kinnen, C Richter, ... RSC Medicinal Chemistry, 2024 | | 2024 |
Jordi MestresChemotargets SLVerified email at chemotargets.com
